الفهرس | Only 14 pages are availabe for public view |
Abstract Background: Nanotechnology is a new branch of science, which is going to be a major driving force behind the impending technological revolution in the 21st century. Although DOX is one of the preferred chemotherapeutic drugs for the treatment of OSCC, several studies pointed out that it was limited due to multidrug resistance (MDR) like the over-expression of DNA damage repair agents as poly (ADP-ribose) polymerase-1 (PARP-1). Accordingly, it seemed very interesting to explore the effect of DOX loaded mesoporous silica nanoparticles (MSNs) with their outstanding properties in comparison to the conventional DOX on HNO-97 cell line, in an attempt to introduce a novel efficient therapeutic modality for OSCC. Aim: The objective of this study is to examine the anticancer effect of doxorubicin loaded MSNs on HNSCC cell lines versus that of doxorubicin only, and to measure the expression of PARP-1 in response to them Methodology: we explored the effect of DOX alone and DOX loaded silica NPs on tongue SCC (HNO-97) cell line. We tested the loading capacity and encapsulation efficiency of DOX on MSNs at the beginning of the experiment. Cell line morphology was also assessed using inverted phase contrast microscope. Then we analyzed the cell viability by Methyl Thiazol Tetrazolium (MTT) assay and degree of apoptosis through expression of caspase-3 by flow cytometry. Finally, we compared the expression PARP-1 in DOX and DOX loaded MSNs by ELISA. Results: It was found that DOX/MSNs showed encapsulation efficiency of 46%. Cell line morphology showed loss of cell adherence, decrease in number and change in shape, which was viii more relevant in DOX/MSNs. In comparison, DOX/MSNs showed superior results to DOX in reduction of cell viability percentage and elevation of caspase-3. In addition, the expression of PARP-1 showed the least value in the DOX/MSNs followed by DOX then the control group. Conclusions: In conclusion, using MSNs in DOX delivery to cancer cells contribute in therapeutic effectiveness of the drug with and help to overcome MDR of HNO-97. |